[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100582259":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":26,"locations":31,"responsibleParty":53,"collaborators":26,"id":57,"slug":26,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":60,"acronym":26,"eligibilityCriteria":61,"healthyVolunteers":58,"sex":62,"minAge":63,"maxAge":64,"enrollmentInfo":65,"targetDuration":26,"studyType":68,"phases":69,"briefSummary":71,"conditions":72,"keywords":26,"overallStatus":34,"whyStopped":26,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":83},{"fullName":5,"class":6},"Tanta University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Control group","PLACEBO_COMPARATOR","The patients will receive placebo capsule placebo tablet 2 h before ERCP.",[13],"Other: Placebo capsule",{"label":15,"type":16,"description":17,"interventionNames":18},"Duloxetine group","ACTIVE_COMPARATOR","The patients will receive 60 mg duloxetine 2 h before ERCP.",[19],"Drug: Duloxetine",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Duloxetine","Duloxetine, a non-opioid neuromodulator, has been widely used to manage neuropathic pain. It possesses dual central and peripheral analgesic properties",[15],null,{"type":6,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Placebo capsule","Placebo will have the same look and appearance of active comparator",[9],[32],{"facility":33,"status":34,"city":35,"state":26,"zip":36,"country":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"Tanta Unuversity","RECRUITING","Tanta","31527","Egypt",{"type":39,"coordinates":40},"Point",[41,42],31.00192,30.78847,{"lat":42,"lon":41},[45,50],{"name":46,"role":47,"phone":48,"phoneExt":26,"email":49},"Mostafa M I Bahaa, PhD","CONTACT","0201025538337","mbahaa@horus.edu.eg",{"name":51,"role":52,"phone":26,"phoneExt":26,"email":26},"Mostafa M Bahaa, PhD","SUB_INVESTIGATOR",{"type":54,"investigatorFullName":55,"investigatorTitle":56,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"PRINCIPAL_INVESTIGATOR","Mostafa Bahaa","Lecturer","100582259",false,"NCT06860984","Evaluating the Safety and Efficacy of Duloxetine in the Prevention of Post Endoscopic Retrograde Cholangiopancreatography Pancreatitis","Inclusion Criteria:\n\n* Age more than 18 years old.\n* Gender: Males and Females\n* Patients with suitable indications for ERCP due to suspected pancreato-biliary disorders.\n* Blood amylase and lipase levels before ERCP are within the normal limits\n\nExclusion Criteria:\n\n* Uncontrolled diabetes mellitus (DM)\n* Severe bleeding tendency\n* Impaired renal function (serum creatinine \\> 2 mg\u002FdL), (creatinine clearance \\\u003C30 ml\u002Fmin)\n* Patients with severe heart disease.\n* Subjects who underwent prior biliary or pancreatic sphincterotomy or dilatation or stenting of either duct.\n* Currently pregnant or nursing\n* Admission due to established pancreatitis before ECRP\n* Unwillingness to undergo ERCP.","ALL","18 Years","65 Years",{"count":66,"type":67},44,"ESTIMATED","INTERVENTIONAL",[70],"PHASE3","Endoscopic retrograde cholangiopancreatography (ERCP (, a key tool that is used in diagnosis and treatment of pancreato-biliary diseases. Post-ERCP pancreatitis (PEP) is the most common and serious complication that can occur following this procedure and can lead to significant morbidity and mortality. A variety of patient-related and procedure-related factors have been associated with higher rates of PEP.",[73],"Biliary Disease","2025-11-17",{"date":76,"type":77},"2025-11-18","ACTUAL",{"date":79,"type":77},"2025-03-10",{"date":81,"type":67},"2026-07-10",{"name":5,"class":6},1]